Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Sangamo
Sort By
Newest First
Sign in
1 / 1
1 / 1
Genome Editing
Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913
Sangamo Therapeutics
PR-M02-19-NI-020
Feb 11, 2019
Preliminary Data
Sangamo Announces Preliminary Data From Champions Study Evaluating SB-913
Sangamo Therapeutics
PR-M08-18-NI-027
Aug 08, 2018
